Difference between revisions of "Venetoclax (Venclexta)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m
Line 8: Line 8:
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*[[Chronic lymphocytic leukemia (CLL/SLL)|Chronic lymphocytic leukemia]]
 
*[[Chronic lymphocytic leukemia (CLL/SLL)|Chronic lymphocytic leukemia]]
 +
*[[Multiple myeloma]]
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
Line 26: Line 27:
  
 
[[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]]
 
[[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]]
 +
[[Category:Multiple myeloma medications]]
  
 
[[Category:Drugs FDA approved in 2016]]
 
[[Category:Drugs FDA approved in 2016]]

Revision as of 14:05, 15 January 2018

General information

Class/mechanism: From the NCI Drug Dictionary: An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. GDC-0199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

History of changes in FDA indication

Also known as

  • Code names: ABT-199, GDC-0199
  • Brand name: Venclexta

References